OptiBiotix Health PLC Extension of term and territories for products (0584B)
28 Enero 2020 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0584B
OptiBiotix Health PLC
28 January 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Extension of term and territories for SlimBiome(R), SlimBiome(R)
Medical and GoFigure(R)
Existing agreements with CTC Holding BV and Cambridge
Commodities Limited
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has extended
the terms and territories of its original distribution agreements
with CTC Holding BV ("CTC Group") as announced on 1 October 2018,
and Cambridge Commodities (as announced on 24 April 2018) covering
the distribution of SlimBiome(R), SlimBiome(R) Medical and
GoFigure(R). The details of the agreements are as follows:-
CTC Group:-
- Extend the product range from the distribution of SlimBiome(R)
to include SlimBiome(R) Medical and GoFigure(R)
- Extend the number of territories with non-exclusive
distribution rights from the Philippines, Vietnam, Indonesia and
Colombia to include the Dominican Republic and Guatemala
- The agreement is for an initial period of 18 months with renewal linked to sales targets
Cambridge Commodities:-
- Provide exclusive distribution rights for SlimBiome(R) in the United Kingdom
- Extend the territory to include Ireland
- The agreement is for an initial period of 24 months with renewal linked to sales targets
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are pleased to announce the extension of
terms and territory for CTC Group and Cambridge Commodities. These
agreements recognise the success of both these partners in building
sales of SlimBiome(R) and extends terms and territory to support
further sale growth, supported by minimum sales targets. This is
another step in extending the geographical reach of SlimBiome(R) as
it builds recurring revenue streams and brand recognition across
the world."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than 20 international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSELFMWESSEEF
(END) Dow Jones Newswires
January 28, 2020 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024